Skip to main content
CVE:AQS

Aequus Pharmaceuticals News Headlines

C$0.15
-0.01 (-6.25 %)
(As of 05/13/2021 03:40 PM ET)
Add
Compare
Today's Range
C$0.15
C$0.15
50-Day Range
C$0.16
C$0.24
52-Week Range
C$0.07
C$0.29
Volume80,650 shs
Average Volume577,276 shs
Market CapitalizationC$19.90 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Aequus Pharmaceuticals (CVE AQS) News Headlines Today

SourceHeadline
Aequus Provides General Update and Reports Record 2020 Financial ResultsAequus Provides General Update and Reports Record 2020 Financial Results
benzinga.com - April 23 at 8:25 AM
Aequus to Present at the 2021 Bloom Burton & Co. Healthcare Investor ConferenceAequus to Present at the 2021 Bloom Burton & Co. Healthcare Investor Conference
markets.businessinsider.com - April 19 at 9:04 AM
Aequus Pharmaceuticals receives $1.48 million from warrant acceleration exercisesAequus Pharmaceuticals receives $1.48 million from warrant acceleration exercises
proactiveinvestors.com - April 6 at 11:38 PM
Aequus Provides update on Warrant AccelerationAequus Provides update on Warrant Acceleration
finance.yahoo.com - April 6 at 8:28 AM
Aequus Pharmaceuticals announces the commercial availability of Evolve preservative-free lubricating eye drops for dry eye careAequus Pharmaceuticals announces the commercial availability of Evolve preservative-free lubricating eye drops for dry eye care
proactiveinvestors.com - March 1 at 3:09 PM
Aequus Pharmaceuticals closes non-brokered private placement with Marc Lustig for aggregate gross proceeds of $1,000,000Aequus Pharmaceuticals closes non-brokered private placement with Marc Lustig for aggregate gross proceeds of $1,000,000
proactiveinvestors.com - March 1 at 3:09 PM
Aequus Closes $1 Million FinancingAequus Closes $1 Million Financing
finance.yahoo.com - February 26 at 11:48 PM
Aequus Announces Anne Stevens Leadership ChangeAequus Announces Anne Stevens' Leadership Change
benzinga.com - November 14 at 11:26 PM
Aequus and partner Medicom Healthcare win Medical Device License for Evolve Intensive Gel to treat Dry Eye DiseaseAequus and partner Medicom Healthcare win Medical Device License for Evolve Intensive Gel to treat Dry Eye Disease
proactiveinvestors.com - October 19 at 1:56 PM
Aequus Receives Approval for New ‘Evolve - Intensive Gel’ Lubricating Eye Drops in CanadaAequus Receives Approval for New ‘Evolve - Intensive Gel’ Lubricating Eye Drops in Canada
markets.businessinsider.com - October 19 at 8:56 AM
AEQUUS PHARMACEUTICALS (AEQ.MU)AEQUUS PHARMACEUTICALS (AEQ.MU)
ca.finance.yahoo.com - October 15 at 11:56 PM
Aequus Pharmaceuticals Inc. Reg (AEQ.SG)Aequus Pharmaceuticals Inc. Reg (AEQ.SG)
au.finance.yahoo.com - October 10 at 9:13 AM
Aequus Pharmaceuticals expands Medicom Healthcare partnership with additional formulation in its Evolve eye product lineAequus Pharmaceuticals expands Medicom Healthcare partnership with additional formulation in its Evolve eye product line
proactiveinvestors.com - September 23 at 1:35 AM
Aequus Announces Expansion of Medicom Partnership and Filing with Health Canada for Additional Evolve Dry Eye ProductAequus Announces Expansion of Medicom Partnership and Filing with Health Canada for Additional Evolve Dry Eye Product
benzinga.com - September 22 at 10:31 AM
Aequus Pharmaceuticals files new medical device licenses for Evolve dry eye products in CanadaAequus Pharmaceuticals files new medical device licenses for Evolve dry eye products in Canada
proactiveinvestors.com - September 19 at 10:29 AM
Aequus Announces Filing of New Medical Device License for Evolve Dry Eye Products in CanadaAequus Announces Filing of New Medical Device License for Evolve Dry Eye Products in Canada
markets.businessinsider.com - September 14 at 3:08 PM
Aequus Pharmaceuticals Inc.Aequus Pharmaceuticals Inc.
barrons.com - September 11 at 12:28 AM
Aequus Pharmaceuticals set to file regulatory approval for Evolve dry eye products in Canada after UK-based partner clears final submission hurdleAequus Pharmaceuticals set to file regulatory approval for Evolve dry eye products in Canada after UK-based partner clears final submission hurdle
proactiveinvestors.com - September 1 at 3:18 AM
Aequus Prepares for Health Canada Regulatory Filing as Partner Receives MDSAP Certificate for Dry Eye ProductsAequus Prepares for Health Canada Regulatory Filing as Partner Receives MDSAP Certificate for Dry Eye Products
markets.businessinsider.com - August 31 at 12:16 PM
Aequus Provides General Update and Second Quarter 2020 Financial HighlightsAequus Provides General Update and Second Quarter 2020 Financial Highlights
benzinga.com - August 27 at 10:48 PM
Aequus Pharmaceuticals welcomes eye care executive Grant Larsen as Chief Commercial OfficerAequus Pharmaceuticals welcomes eye care executive Grant Larsen as Chief Commercial Officer
proactiveinvestors.com - August 20 at 2:55 PM
Aequus Completes C$2.5 million Equity FinancingAequus Completes C$2.5 million Equity Financing
benzinga.com - August 6 at 1:52 PM
Aequus Pharmaceuticals to raise funds to launch its Evolve line of dry eye productsAequus Pharmaceuticals to raise funds to launch its Evolve line of dry eye products
www.proactiveinvestors.com - August 1 at 5:33 PM
Aequus Announces "Best Efforts" Public OfferingAequus Announces "Best Efforts" Public Offering
www.benzinga.com - July 28 at 1:24 PM
Aequus Pharmaceuticals: The Moment Is NowAequus Pharmaceuticals: The Moment Is Now
seekingalpha.com - July 24 at 6:32 PM
Aequus Pharmaceuticals sees 1Q revenue soar 76% driven by impressive sales momentumAequus Pharmaceuticals sees 1Q revenue soar 76% driven by impressive sales momentum
www.proactiveinvestors.com - June 1 at 1:00 PM
Aequus Provides General Update and First Quarter 2020 Financial HighlightsAequus Provides General Update and First Quarter 2020 Financial Highlights
markets.businessinsider.com - June 1 at 1:00 PM
Full interview: Aequus Pharmaceuticals off to a great start in 2020 after record 4th quarter in 2019Full interview: Aequus Pharmaceuticals off to a great start in 2020 after record 4th quarter in 2019
www.proactiveinvestors.com - May 4 at 10:02 PM
Aequus Pharmaceuticals posts 44% rise in 4Q revenue rounding out solid financial gains in 2019Aequus Pharmaceuticals posts 44% rise in 4Q revenue rounding out solid financial gains in 2019
www.proactiveinvestors.com - April 30 at 6:11 PM
Aequus Provides General Update and 2019 Financial HighlightsAequus Provides General Update and 2019 Financial Highlights
markets.businessinsider.com - April 29 at 11:31 PM
Aequus Pharmaceuticals advancing Evolve line of preservative-free dry eye products into CanadaAequus Pharmaceuticals advancing Evolve line of preservative-free dry eye products into Canada
www.proactiveinvestors.com - April 21 at 3:07 PM
Aequus Announces Positive Update on Dry Eye Product Launch PlansAequus Announces Positive Update on Dry Eye Product Launch Plans
www.benzinga.com - April 21 at 3:07 PM
Aequus Pharmaceuticals has adequate funds and cash flow to operate business amid coronavirus outbreakAequus Pharmaceuticals has adequate funds and cash flow to operate business amid coronavirus outbreak
www.proactiveinvestors.com - March 23 at 2:36 PM
A Message from the CEO of Aequus PharmaceuticalsA Message from the CEO of Aequus Pharmaceuticals
www.globenewswire.com - March 23 at 9:35 AM
Aequus Announces Appointment of New Director to its Board & Stock Option GrantAequus Announces Appointment of New Director to its Board & Stock Option Grant
www.globenewswire.com - February 19 at 2:03 PM
Aequus Pharmaceuticals welcomes Stu Fowler as strategic commercial advisor; Ian Ball transitions into Medicom roleAequus Pharmaceuticals welcomes Stu Fowler as strategic commercial advisor; Ian Ball transitions into Medicom role
www.proactiveinvestors.com - February 3 at 2:39 PM
Aequus Pharmaceuticals hails further boost to its growing Sandoz tacrolimus revenues across CanadaAequus Pharmaceuticals hails further boost to its growing Sandoz tacrolimus revenues across Canada
www.proactiveinvestors.com - January 16 at 10:28 PM
NA Proactive news snapshot: Aequus Pharmaceuticals, Nano One Materials, Next Green Wave, Metalla Royalty & Streaming UPDATE …NA Proactive news snapshot: Aequus Pharmaceuticals, Nano One Materials, Next Green Wave, Metalla Royalty & Streaming UPDATE …
www.proactiveinvestors.com - January 16 at 5:28 PM
NA Proactive news snapshot: Aequus, Ceylon Graphite, Para Resources, NexTech AR Solutions UPDATE …NA Proactive news snapshot: Aequus, Ceylon Graphite, Para Resources, NexTech AR Solutions UPDATE …
www.proactiveinvestors.com - January 10 at 3:27 PM
Aequus to broaden patient reimbursement in Canada for glaucoma-treatment product VistitanAequus to broaden patient reimbursement in Canada for glaucoma-treatment product Vistitan
www.proactiveinvestors.com - January 10 at 3:27 PM
Aequus to Broaden Vistitan Reimbursement for Patients in CanadaAequus to Broaden Vistitan Reimbursement for Patients in Canada
www.benzinga.com - January 10 at 3:27 PM
Aequus and Medicom Healthcare ink pact to advance ophthalmology products in USAequus and Medicom Healthcare ink pact to advance ophthalmology products in US
www.proactiveinvestors.com - December 13 at 2:44 PM
Aequus and Medicom Healthcare Sign Exclusive Term Sheet To Jointly Advance Ophthalmology Products Into The USAAequus and Medicom Healthcare Sign Exclusive Term Sheet To Jointly Advance Ophthalmology Products Into The USA
www.globenewswire.com - December 13 at 2:44 PM
Aequus Pharmaceuticals posts 3Q results, teases 2020 revenue boost from ophthalmology partnershipAequus Pharmaceuticals posts 3Q results, teases 2020 revenue boost from ophthalmology partnership
www.proactiveinvestors.com - December 2 at 12:28 PM
Aequus Provides Third Quarter 2019 Financial HighlightsAequus Provides Third Quarter 2019 Financial Highlights
markets.businessinsider.com - November 29 at 4:52 PM
Imagine Owning Aequus Pharmaceuticals (CVE:AQS) While The Price Tanked 56%Imagine Owning Aequus Pharmaceuticals (CVE:AQS) While The Price Tanked 56%
finance.yahoo.com - October 25 at 12:43 PM
Aequus Pharmaceuticals highlights new research showing Vistitans effectiveness at treating glaucomaAequus Pharmaceuticals highlights new research showing Vistitan's effectiveness at treating glaucoma
www.proactiveinvestors.com - October 18 at 1:49 PM
Aequus Highlights Study Indicating Vistitan as the Most Effective Treatment for GlaucomaAequus Highlights Study Indicating Vistitan as the Most Effective Treatment for Glaucoma
markets.businessinsider.com - October 18 at 8:49 AM
Should You Worry About Aequus Pharmaceuticals Inc.s (CVE:AQS) CEO Pay?Should You Worry About Aequus Pharmaceuticals Inc.'s (CVE:AQS) CEO Pay?
ca.finance.yahoo.com - September 10 at 5:16 PM
Aequus Pharmaceuticals returns to revenue growth in second quarterAequus Pharmaceuticals returns to revenue growth in second quarter
www.proactiveinvestors.com - August 27 at 9:13 PM
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.